Biocartis Group (BCART.BR) Stock Price
Biocartis Group Price
Revenue has compounded at 32.1% per year over the past 10 years to 57.48 M EUR. Biocartis Group's net margin stands at -113.7%, up from -173.1% several years earlier.
Biocartis Group stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biocartis Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biocartis Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biocartis Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biocartis Group Price |
|---|---|
| 1/21/2026 | 0.29 EUR |
| 1/20/2026 | 0.29 EUR |
| 1/19/2026 | 0.29 EUR |
| 1/16/2026 | 0.29 EUR |
| 1/15/2026 | 0.29 EUR |
| 1/14/2026 | 0.29 EUR |
| 1/13/2026 | 0.29 EUR |
| 1/12/2026 | 0.29 EUR |
| 1/9/2026 | 0.29 EUR |
| 1/8/2026 | 0.29 EUR |
| 1/7/2026 | 0.29 EUR |
| 1/6/2026 | 0.29 EUR |
| 1/5/2026 | 0.29 EUR |
| 1/2/2026 | 0.29 EUR |
| 12/31/2025 | 0.29 EUR |
| 12/30/2025 | 0.29 EUR |
| 12/29/2025 | 0.29 EUR |
| 12/24/2025 | 0.29 EUR |
| 12/23/2025 | 0.29 EUR |
| 12/22/2025 | 0.29 EUR |
| 12/19/2025 | 0.29 EUR |
| 12/18/2025 | 0.29 EUR |
| 12/17/2025 | 0.29 EUR |
| 12/16/2025 | 0.29 EUR |
| 12/15/2025 | 0.29 EUR |
| 12/12/2025 | 0.29 EUR |
| 12/11/2025 | 0.29 EUR |
| 12/10/2025 | 0.29 EUR |
| 12/9/2025 | 0.29 EUR |
| 12/8/2025 | 0.29 EUR |
| 12/5/2025 | 0.29 EUR |
| 12/4/2025 | 0.29 EUR |
| 12/3/2025 | 0.29 EUR |
| 12/2/2025 | 0.29 EUR |
| 12/1/2025 | 0.29 EUR |
| 11/28/2025 | 0.29 EUR |
| 11/27/2025 | 0.29 EUR |
| 11/26/2025 | 0.29 EUR |
| 11/25/2025 | 0.29 EUR |
| 11/24/2025 | 0.29 EUR |
| 11/21/2025 | 0.29 EUR |
| 11/20/2025 | 0.29 EUR |
| 11/19/2025 | 0.29 EUR |
| 11/18/2025 | 0.29 EUR |
| 11/17/2025 | 0.29 EUR |
| 11/14/2025 | 0.29 EUR |
| 11/13/2025 | 0.29 EUR |
| 11/12/2025 | 0.29 EUR |
| 11/11/2025 | 0.29 EUR |
| 11/10/2025 | 0.29 EUR |
| 11/7/2025 | 0.29 EUR |
| 11/6/2025 | 0.29 EUR |
| 11/5/2025 | 0.29 EUR |
| 11/4/2025 | 0.29 EUR |
| 11/3/2025 | 0.29 EUR |
| 10/31/2025 | 0.29 EUR |
| 10/30/2025 | 0.29 EUR |
| 10/29/2025 | 0.29 EUR |
| 10/28/2025 | 0.29 EUR |
| 10/27/2025 | 0.29 EUR |
| 10/24/2025 | 0.29 EUR |
| 10/23/2025 | 0.29 EUR |
| 10/22/2025 | 0.29 EUR |
| 10/21/2025 | 0.29 EUR |
| 10/20/2025 | 0.29 EUR |
| 10/17/2025 | 0.29 EUR |
| 10/16/2025 | 0.29 EUR |
| 10/15/2025 | 0.29 EUR |
| 10/14/2025 | 0.29 EUR |
| 10/13/2025 | 0.29 EUR |
| 10/10/2025 | 0.29 EUR |
| 10/9/2025 | 0.29 EUR |
| 10/8/2025 | 0.29 EUR |
| 10/7/2025 | 0.29 EUR |
| 10/6/2025 | 0.29 EUR |
| 10/3/2025 | 0.29 EUR |
| 10/2/2025 | 0.29 EUR |
| 10/1/2025 | 0.29 EUR |
| 9/30/2025 | 0.29 EUR |
| 9/29/2025 | 0.29 EUR |
| 9/26/2025 | 0.29 EUR |
| 9/25/2025 | 0.29 EUR |
| 9/24/2025 | 0.29 EUR |
| 9/23/2025 | 0.29 EUR |
| 9/22/2025 | 0.29 EUR |
| 9/19/2025 | 0.29 EUR |
| 9/18/2025 | 0.29 EUR |
| 9/17/2025 | 0.29 EUR |
| 9/16/2025 | 0.29 EUR |
| 9/15/2025 | 0.29 EUR |
| 9/12/2025 | 0.29 EUR |
| 9/11/2025 | 0.29 EUR |
| 9/10/2025 | 0.29 EUR |
| 9/9/2025 | 0.29 EUR |
| 9/8/2025 | 0.29 EUR |
| 9/5/2025 | 0.29 EUR |
| 9/4/2025 | 0.29 EUR |
| 9/3/2025 | 0.29 EUR |
| 9/2/2025 | 0.29 EUR |
| 9/1/2025 | 0.29 EUR |
| 8/29/2025 | 0.29 EUR |
| 8/28/2025 | 0.29 EUR |
| 8/27/2025 | 0.29 EUR |
| 8/26/2025 | 0.29 EUR |
| 8/25/2025 | 0.29 EUR |
| 8/22/2025 | 0.29 EUR |
| 8/21/2025 | 0.29 EUR |
| 8/20/2025 | 0.29 EUR |
| 8/19/2025 | 0.29 EUR |
| 8/18/2025 | 0.29 EUR |
| 8/15/2025 | 0.29 EUR |
| 8/14/2025 | 0.29 EUR |
| 8/13/2025 | 0.29 EUR |
| 8/12/2025 | 0.29 EUR |
| 8/11/2025 | 0.29 EUR |
Biocartis Group Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocartis Group Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.00 | 8.00 | 8.00 | 13.00 | 12.00 | 20.00 | 27.00 | 37.00 | 43.00 | 48.00 | 57.00 | 58.00 | 76.00 | 103.00 |
| – | 166.67 | – | 62.50 | -7.69 | 66.67 | 35.00 | 37.04 | 16.22 | 11.63 | 18.75 | 1.75 | 31.03 | 35.53 |
| 66.67 | 75.00 | 50.00 | 76.92 | 50.00 | 60.00 | 44.44 | 43.24 | 37.21 | 29.17 | 47.37 | 47.37 | 47.37 | 47.37 |
| 2.00 | 6.00 | 4.00 | 10.00 | 6.00 | 12.00 | 12.00 | 16.00 | 16.00 | 14.00 | 27.00 | 27.47 | 36.00 | 48.79 |
| -35.00 | -26.00 | -29.00 | -39.00 | -50.00 | -43.00 | -46.00 | -55.00 | -46.00 | -62.00 | -47.00 | -36.00 | -18.00 | 4.00 |
| -1,166.67 | -325.00 | -362.50 | -300.00 | -416.67 | -215.00 | -170.37 | -148.65 | -106.98 | -129.17 | -82.46 | -62.07 | -23.68 | 3.88 |
| -44.00 | -35.00 | -9.00 | -39.00 | -49.00 | -41.00 | -48.00 | -64.00 | -62.00 | -71.00 | -65.00 | – | – | -47.00 |
| – | -20.45 | -74.29 | 333.33 | 25.64 | -16.33 | 17.07 | 33.33 | -3.13 | 14.52 | -8.45 | – | – | – |
| 40.45 | 47.43 | 47.43 | 43.46 | 45.15 | 51.17 | 56.07 | 64.28 | 64.90 | 65.97 | 63.13 | 63.13 | 63.13 | 63.13 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biocartis Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biocartis Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biocartis Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biocartis Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biocartis Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biocartis Group stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocartis Group Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biocartis Group business model & stock analysis
Biocartis Group SWOT Analysis
Strengths
Biocartis Group NV is a leading biotech company with a strong market presence and a diverse portfolio of innovative diagnostic products. The company has developed proprietary molecular diagnostic platforms that offer rapid and accurate results, providing a competitive advantage.
Biocartis has established strategic partnerships with renowned global healthcare organizations, enhancing its access to resources, expertise, and distribution networks. This allows for efficient commercialization, market penetration, and continued growth.
Weaknesses
Biocartis Group NV faces challenges related to its limited geographic reach and potential dependence on partner collaborations for global expansion. This may limit its market share and growth opportunities in certain regions.
The company's success relies heavily on the continuous development of technologically advanced diagnostic platforms. Failure to innovate and keep up with rapid advancements in the industry may result in loss of market share and competitive edge.
Opportunities
The increasing demand for personalized medicine and the growing prevalence of chronic diseases present significant opportunities for Biocartis Group NV to expand its product portfolio and cater to evolving healthcare needs. The company can leverage its expertise to develop new diagnostic assays and capture a larger market share.
Expanding into emerging markets, such as Asia-Pacific and Latin America, can tap into unmet needs and unlock substantial growth potential for Biocartis. Capitalizing on the rising adoption of molecular diagnostics in these regions can lead to market leadership and enhanced profitability.
Threats
Intense competition from larger, well-established biotech companies and the presence of numerous local players pose a threat to Biocartis Group NV's market positioning. The company must continuously differentiate its offerings and stay ahead in terms of technological advancements, product quality, and customer service to mitigate this risk.
Regulatory and compliance requirements, especially in the healthcare sector, can pose challenges and increase costs for Biocartis. Adhering to evolving regulations and ensuring seamless product approvals across multiple jurisdictions is crucial for sustained growth.
Biocartis Group Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biocartis Group historical P/E ratio, EBIT multiple, and P/S ratio
Biocartis Group annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biocartis Group shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the Biocartis Group stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Biocartis Group shareholder structure
| % | Name |
|---|---|
4.25894% | |
0.02742% | |
0.00433% |
Biocartis Group Beneficial Ownership Filings (SEC 13D/G)
Biocartis Group Executives and Management Board
11 members · avg. age 59 · 27 % women
Management
Mr. Roger Moody
Chief Executive Officer, Director · since 2023
Mr. George Cardoza (61)
Chief Financial Officer and Head of Service Delivery
Mr. Piet Houwen (55)
Chief Operating Officer, Representative of Scmiles BV
Dr. W. Michael Korn
Chief Medical and Scientific Officer
Ms. Renate Degrave
Head of Investor Relations and Corporate Communications
Board of Directors
Mr. Herman Verrelst (49)
Executive Chairman of the Board · since 2017
Dr. Christian Reinaudo (70)
Lead Independent Director
Mr. Luc Gijsens (70)
Non-Executive Independent Director, Representative of Luc Gijsens BV
Dr. Christine Kuslich (55)
Non-Executive Independent Director
Mrs. Ann-Christine Sundell (59)
Non-Executive Independent Director
Mr. Bryan Dechairo (50)
Non-Executive Independent Director
Frequently asked questions about Biocartis Group
The business model of Biocartis Group NV focuses on the development and commercialization of innovative diagnostics solutions. Biocartis specializes in molecular diagnostics, offering a wide range of reliable and easy-to-use molecular diagnostic platforms that enable fast and accurate testing for various diseases and conditions. By combining advanced technology and extensive research expertise, Biocartis aims to provide healthcare professionals with efficient tools for personalized medicine, leading to better patient outcomes. With a customer-centric approach and diverse product portfolio, Biocartis strives to address unmet medical needs and improve the diagnostics landscape.
Biocartis Group NV is primarily active in the healthcare and life sciences industries.
The main competitors of Biocartis Group NV in the market include companies such as Illumina, Thermo Fisher Scientific, and QIAGEN.
Biocartis Group NV is a leading molecular diagnostics company, headquartered in Mechelen, Belgium. Founded in 2007, Biocartis focuses on providing innovative diagnostic solutions to improve patient outcomes in the field of oncology. The company developed the Idylla™ platform, a fully automated molecular diagnostics system, which enables fast and accurate testing of various biomarkers. Biocartis has successfully partnered with renowned pharmaceutical companies and diagnostic laboratories worldwide to deliver personalized medicine solutions. With its strong commitment to research and development, Biocartis continues to revolutionize the molecular diagnostics industry, contributing to advancements in precision medicine and patient care.
Biocartis Group NV, a leading molecular diagnostics company, has achieved several significant milestones. It successfully launched its flagship molecular diagnostics platform, Idylla™, which enables fast and accurate diagnostic testing for a wide range of diseases. The company has also established partnerships with renowned institutions and organizations, strengthening its global presence and market reach. Biocartis Group NV has consistently demonstrated its commitment to innovation, regularly introducing new assays and expanding the applications of its technology. Moreover, the company has obtained various regulatory clearances and certifications, reaffirming its dedication to providing reliable and high-quality diagnostic solutions. Biocartis Group NV's relentless pursuit of advancements in molecular diagnostics has positioned it as a key player in the industry.
Biocartis Group NV is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, particularly in Belgium, where it is headquartered. Biocartis also has a significant presence in the United States, as it operates a subsidiary in New Jersey. Additionally, the company has expanded its reach to other regions, including Asia, Africa, and the Middle East. By establishing strategic partnerships and collaborations, Biocartis aims to serve the global healthcare market with its innovative molecular diagnostics solutions.
Biocartis Group NV is a prominent company known for its strong values and corporate philosophy. With a focus on innovation and advanced technologies, Biocartis Group NV is passionate about improving personalized medicine. The company firmly believes in building partnerships and collaborations to enhance the efficiency and effectiveness of healthcare delivery. By integrating molecular diagnostics, Biocartis Group NV aims to revolutionize diagnostics and enable better patient outcomes. Through their continuous commitment to excellence, Biocartis Group NV strives to be a leader in precision medicine, offering reliable and accurate testing solutions.
7 analysts currently rate the Biocartis Group stock: 0 recommend buying, 2 holding and 5 selling.
The Biocartis Group share (BCART.BR) is listed on 5 stock exchanges, including: Frankfurt (8XB.F), Düsseldorf (8XB.DU), London (0R72.L).
The Biocartis Group NV is a Belgium-based medical technology company that offers innovative diagnostic solutions for the field of molecular diagnostics. It aims to simplify, accelerate, and personalize the diagnosis of cancer and infectious diseases through the use of technology. Biocartis combines proprietary platforms with collaborations with leading pharmaceutical and diagnostic companies. Biocartis' core business is the development and marketing of its molecular diagnostic platforms, which are based on the proprietary technology of the original Idylla™ platform. This platform allows for the identification of disease-relevant biomarkers in tissue or blood samples of patients and their diagnosis within 15 to 150 minutes through a rapid test. Biocartis offers the following Idylla™ platforms: - Idylla™ Console: A fully automated diagnostic system for the rapid and precise analysis of biomarkers in tissue samples. - Idylla™ cartridges: A range of test cartridges specifically designed for use with the Idylla™ platform, typically detecting biomarkers for cancer and infectious diseases. - Idylla™ global network: A workspace connecting test centers and laboratories worldwide, allowing for real-time exchange of patient data and test results. The Idylla™ platforms aim to compete with traditional histopathological diagnostics, which can be time-consuming and prone to misinterpretation. They offer faster and more accurate diagnostics, enabling physicians and clinics to treat more quickly and effectively. In addition to its Idylla™ platforms, Biocartis also offers a range of research products including: - MyCartis™: A platform for protein analysis that allows researchers to quantitatively measure proteins in a very short time. - AMR Rapid Test: A rapid test for diagnosing antimicrobial resistances, determining the sensitivity of bacteria to antibiotics. - Liquid biopsy tests: Tests for detecting cancer in blood by detecting circulating tumor cells or tumor DNA. An important pillar of Biocartis' business model is its collaboration with pharmaceutical and diagnostic companies to develop new tests for the Idylla™ platform. The company has partnerships and collaborations with leading companies in the industry, including Amgen, Merck, Bristol-Myers Squibb, Qiagen, and Nestlé Health Science. This collaboration allows Biocartis to develop new biomarkers and test cartridges for its platforms, expanding the offering for physicians and patients. In summary, the Biocartis Group NV offers innovative molecular diagnostic platforms based on proprietary technology, enabling faster and more accurate diagnosis of cancer and infectious diseases. The company leverages its expertise and collaboration with leading companies in the industry to develop new tests for its platforms and expand the offering for physicians and patients. Please, let me know if I can help you with anything else.
The revenue cannot currently be calculated for Biocartis Group.
The profit cannot currently be calculated for Biocartis Group.
The P/E ratio cannot be calculated for Biocartis Group at the moment.
The P/S cannot be calculated for Biocartis Group currently.
The Eulerpool Quality Score for Biocartis Group is 4/10.
The ISIN of Biocartis Group is BE0974281132. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biocartis Group is A14R82. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biocartis Group is BCART.BR. The ticker symbol is used to trade Biocartis Group shares on the stock exchange.
Biocartis Group paid dividends every year for the past 0 years.
Biocartis Group is assigned to the 'Health' sector.
The dividends of Biocartis Group are distributed in EUR.
Biocartis Group stock
Biocartis Group Peer Group
Biocartis Group Ticker
Biocartis Group FIGI
All fundamentals and in-depth analysis of Biocartis Group
Our stock analysis for Biocartis Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocartis Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.